Recursion(US:RXRX) ZACKS·2025-10-28 22:51Company Performance - Recursion Pharmaceuticals (RXRX) closed at $5.91, reflecting a decline of -6.19% from the previous day, underperforming the S&P 500 which gained 0.23% [1] - Over the past month, the company's shares increased by 28.31%, outperforming the Medical sector's gain of 5.57% and the S&P 500's gain of 3.57% [1] Upcoming Earnings - The company is expected to report an EPS of -$0.38, which is a decrease of 11.76% compared to the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $17.45 million, down 33.11% from the previous year [2] Full Year Estimates - For the full year, analysts expect earnings of -$1.53 per share and revenue of $72.38 million, representing changes of +9.47% and +23.02% respectively from last year [3] Analyst Estimates - Recent modifications to analyst estimates indicate a changing outlook for Recursion Pharmaceuticals, with positive revisions suggesting a favorable business health and profitability [4] - The Zacks Rank system, which assesses these estimate changes, currently ranks Recursion Pharmaceuticals at 4 (Sell) [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Recursion Pharmaceuticals, holds a Zacks Industry Rank of 89, placing it in the top 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]